Needham & Company LLC reissued their buy rating on shares of Immuneering (NASDAQ:IMRX - Free Report) in a report issued on Friday,Benzinga reports. Needham & Company LLC currently has a $12.00 target price on the stock.
A number of other research firms have also issued reports on IMRX. Chardan Capital reiterated a "buy" rating and issued a $13.00 target price on shares of Immuneering in a research note on Wednesday, January 8th. Morgan Stanley cut Immuneering from an "equal weight" rating to an "underweight" rating in a report on Friday, December 13th.
Check Out Our Latest Report on Immuneering
Immuneering Trading Down 3.9 %
IMRX traded down $0.07 during trading on Friday, hitting $1.73. 76,631 shares of the company's stock were exchanged, compared to its average volume of 2,386,377. The stock has a 50 day moving average price of $1.79 and a 200 day moving average price of $2.00. Immuneering has a 1 year low of $1.00 and a 1 year high of $3.83. The firm has a market cap of $53.72 million, a P/E ratio of -0.88 and a beta of -0.32.
Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.16). Analysts forecast that Immuneering will post -1.86 earnings per share for the current fiscal year.
Institutional Trading of Immuneering
Large investors have recently modified their holdings of the business. Corsair Capital Management L.P. purchased a new position in Immuneering in the third quarter valued at about $25,000. Tang Capital Management LLC acquired a new position in shares of Immuneering in the 4th quarter valued at approximately $27,000. Marshall Wace LLP purchased a new position in shares of Immuneering during the 4th quarter valued at approximately $47,000. First Manhattan CO. LLC. acquired a new stake in shares of Immuneering during the fourth quarter worth approximately $71,000. Finally, XTX Topco Ltd increased its stake in shares of Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after buying an additional 20,871 shares during the last quarter. 67.65% of the stock is currently owned by institutional investors and hedge funds.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Further Reading
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
